Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled therapies for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. Its pipeline features optimized inhaled formulations of established antifibrotic medicines, such as AP01, an inhaled version of pirfenidone for progressive pulmonary fibrosis, and AP02, an inhaled formulation of nintedanib for idiopathic pulmonary fibrosis. This nebulization approach aims to deliver medication directly to the lung tissue, potentially improving efficacy while reducing the significant side effects and tolerability issues associated with current oral therapies that often limit patient compliance. Avalyn Pharma Inc. focuses on addressing the unmet needs in treating these progressive conditions by enhancing local drug delivery and minimizing systemic exposure. Founded in 2011 and headquartered in Boston, Massachusetts, the company operates in the biopharmaceutical sector targeting serious rare lung disorders.
$37.38
+$1.92 (+5.41%)
EOD Aug 12, 2026
Negative free cash flow of -$82M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$85M
▼ -71.3% YoY
Op. Margin
—
ROIC
-8642.38%
Cash Flow & Balance Sheet
FCF (TTM)
-$82M
▼ -68.8% YoY
Op. Cash Flow (TTM)
-$81M
▼ -68.5% YoY
Net Debt
-$137M
Net Cash Position
Cash & Equiv.
$138M
Continue Research
Avalyn Pharma (AVLN)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Avalyn Pharma scores 18/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Avalyn Pharma scores 18 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -8,642.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh AVLN's valuation and scores 18/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.